WO2007132291A3 - Biomarkers for pre-form of type 2 diabetes and methods for detecting the presence of absence of a pre-form of type 2 diabetes - Google Patents

Biomarkers for pre-form of type 2 diabetes and methods for detecting the presence of absence of a pre-form of type 2 diabetes Download PDF

Info

Publication number
WO2007132291A3
WO2007132291A3 PCT/IB2006/004112 IB2006004112W WO2007132291A3 WO 2007132291 A3 WO2007132291 A3 WO 2007132291A3 IB 2006004112 W IB2006004112 W IB 2006004112W WO 2007132291 A3 WO2007132291 A3 WO 2007132291A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetes
type
methods
biomarkers
absence
Prior art date
Application number
PCT/IB2006/004112
Other languages
French (fr)
Other versions
WO2007132291A2 (en
Inventor
Petra Budde
Hans-Dieter Zucht
Suzanne Neitz
Annette Appel
Original Assignee
Digilab Inc
Petra Budde
Hans-Dieter Zucht
Suzanne Neitz
Annette Appel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Digilab Inc, Petra Budde, Hans-Dieter Zucht, Suzanne Neitz, Annette Appel filed Critical Digilab Inc
Priority to JP2009510561A priority Critical patent/JP2009537812A/en
Priority to EP06849465A priority patent/EP2059818A2/en
Publication of WO2007132291A2 publication Critical patent/WO2007132291A2/en
Publication of WO2007132291A3 publication Critical patent/WO2007132291A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods for the diagnosis, prognosis, and stratification of pre-forms of metabolic disorders, particularly type 2 diabetes or other conditions or diseases associated with insulin deficiencies, such impaired glucose tolerance. Peptides which allow alone or in combination the diagnosis, prognosis or stratification of pre-forms of type 2 diabetes. In addition, the present invention relates to test kits for said methods as well as new peptide molecules and their use.
PCT/IB2006/004112 2006-05-15 2006-10-16 Biomarkers for pre-form of type 2 diabetes and methods for detecting the presence of absence of a pre-form of type 2 diabetes WO2007132291A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2009510561A JP2009537812A (en) 2006-05-15 2006-10-16 Biomarker for type 2 diabetes preform and method for detecting the presence or absence of type 2 diabetes preform
EP06849465A EP2059818A2 (en) 2006-05-15 2006-10-16 Biomarkers for pre-form of type 2 diabetes and methods for detecting the presence of absence of a pre-form of type 2 diabetes

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US74724506P 2006-05-15 2006-05-15
US60/747,245 2006-05-15
US84052506P 2006-08-28 2006-08-28
US60/840,525 2006-08-28

Publications (2)

Publication Number Publication Date
WO2007132291A2 WO2007132291A2 (en) 2007-11-22
WO2007132291A3 true WO2007132291A3 (en) 2008-12-18

Family

ID=38694265

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/004112 WO2007132291A2 (en) 2006-05-15 2006-10-16 Biomarkers for pre-form of type 2 diabetes and methods for detecting the presence of absence of a pre-form of type 2 diabetes

Country Status (3)

Country Link
EP (1) EP2059818A2 (en)
JP (1) JP2009537812A (en)
WO (1) WO2007132291A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110008901A1 (en) * 2009-07-07 2011-01-13 Kiernan Urban A Apolipoprotein ciii in pre- and type 2 diabetes
EP2494364A1 (en) * 2009-10-29 2012-09-05 Tethys Bioscience, Inc. Protein and lipid biomarkers providing consistent improvement to the prediction of type 2 diabetes
GB2476789A (en) 2009-11-10 2011-07-13 Gl Holdings Inc Bv Use of thymosin for treatment of type 2 diabetes
JP6012923B2 (en) * 2010-12-22 2016-10-25 株式会社Ｍｃｂｉ Biomarker for cognitive dysfunction disease and method for detecting cognitive dysfunction disease using the biomarker
US9751922B2 (en) 2012-04-06 2017-09-05 National Institute Of Advanced Industrial Science And Technology Protein tag, tagged protein, and protein purification method
CA3129057C (en) * 2012-10-03 2023-03-07 Csl Behring Ag A method of purifying proteins
US9534029B2 (en) 2012-10-03 2017-01-03 Csl Behring Ag Method of purifying proteins
US20210132089A1 (en) * 2017-03-10 2021-05-06 The Regents Of The University Of California Method for diagnosing risk for inflammatory disease through glycan profiling

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001081919A2 (en) * 2000-04-27 2001-11-01 Bionebraska, Inc. Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose
WO2002088742A2 (en) * 2001-04-30 2002-11-07 Syn.X Pharma, Inc. Biopolymer marker having a molecular weight of 2937 daltons
US20030181364A1 (en) * 1997-05-15 2003-09-25 Gary Ruvkun Therapeutic and diagnostic tools for impaired glucose tolerance conditions
WO2004078777A2 (en) * 2003-03-04 2004-09-16 Biorexis Pharmaceutical Corporation Dipeptidyl-peptidase protected proteins

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030181364A1 (en) * 1997-05-15 2003-09-25 Gary Ruvkun Therapeutic and diagnostic tools for impaired glucose tolerance conditions
WO2001081919A2 (en) * 2000-04-27 2001-11-01 Bionebraska, Inc. Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose
WO2002088742A2 (en) * 2001-04-30 2002-11-07 Syn.X Pharma, Inc. Biopolymer marker having a molecular weight of 2937 daltons
WO2004078777A2 (en) * 2003-03-04 2004-09-16 Biorexis Pharmaceutical Corporation Dipeptidyl-peptidase protected proteins

Also Published As

Publication number Publication date
EP2059818A2 (en) 2009-05-20
JP2009537812A (en) 2009-10-29
WO2007132291A2 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
WO2007132291A3 (en) Biomarkers for pre-form of type 2 diabetes and methods for detecting the presence of absence of a pre-form of type 2 diabetes
WO2010005982A3 (en) Multiplexed biomarkers of insulin resistance
WO2007137072A3 (en) Assays for diagnosing and evaluating treatment options for fabry disease
EP4335932A3 (en) Methods of monitoring conditions by sequence analysis
WO2009014639A3 (en) Biomarkers for pre-diabetes, cardiovascular diseases, and other metabolic-syndrome related disorders and methods using the same
UA96139C2 (en) Anti-neuropilin-1 (nrp1) antibody
WO2007103541A3 (en) Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
WO2005114190A3 (en) Methods of identifying biomarkers
UA101167C2 (en) Pharmaceutical composition useful for the treatment of ocular disease
WO2007028162A3 (en) Methods and compositions for identifying biomarkers useful in diagnosis and/or treatment of biological states
NZ596037A (en) Fgf21 mutants and uses thereof
WO2010037859A3 (en) Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family
WO2010041046A8 (en) Granin proteins as markers of heart disease
WO2010092164A3 (en) Bacterial dna as markers of cardiovascular and/or metabolic disease
WO2008033427A3 (en) Compositions and methods for detection of lysosomal storage disease
WO2010115745A3 (en) Biomarkers, methods and kits for the diagnosis of rheumatoid arthritis
BR112014020213A2 (en) biomarkers for the diagnosis, prognosis, evaluation and stratification of syncope therapy
WO2009114712A3 (en) Assays for diagnosing and evaluating treatment options for pompe disease
WO2006085121A3 (en) Vgp peptide fragments as biomarkers for schizophrenic and bipolar disorders
WO2008065682A3 (en) Genetic susceptibility variants of type 2 diabetes mellitus
WO2008034622A3 (en) A method of detecting and/or quantifying expression of a target protein candidate in a cell, and a method of identifying a target protein of a small molecule modulator
MX339765B (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure.
EP2463300A3 (en) GalNAc specific binding molecules and uses thereof
WO2010057647A3 (en) Methods and compositions for the diagnosis and treatment of diabetes
WO2007057548A3 (en) Method for diagnosticating hepatic diseases and for screening molecules for treating said diseases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2009510561

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006849465

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06849465

Country of ref document: EP

Kind code of ref document: A2